MYOS (formerly known as MYOS RENS) is an emerging BioTherapeutics and BioNutrition company focused on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and chronic and acute muscle diseases. MYOS is the owner of MYO-T12, the first clinically demonstrated natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards for muscle health.